Metabotropic Glutamate Receptor 3 - Pipeline Review, H1 2019

Global Markets Direct’s, ‘Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Pipeline Review, H1 2019’, provides in depth analysis on Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Central Nervous System and Oncology under development targeting Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

  • Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3)

- The report reviews Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) targeted therapeutics and enlists all their major and minor projects

- The report assesses Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Addex Therapeutics Ltd

Denovo Biopharma LLC

Domain Therapeutics SA

Eli Lilly and Co

Addex Therapeutics Ltd

Denovo Biopharma LLC

Domain Therapeutics SA

Eli Lilly and Co

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Overview

Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Companies Involved in Therapeutics Development

Addex Therapeutics Ltd

Denovo Biopharma LLC

Domain Therapeutics SA

Eli Lilly and Co

Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Drug Profiles

DT-010991 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DT-011088 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LY-3020371 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LY-341495 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pomaglumetad methionil - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize mGLUR3 for Glioma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Modulate mGlu3 Receptor for Neurodegenerative Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VU-0092273 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VU-0650786 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Dormant Products

Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Discontinued Products

Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Product Development Milestones

Featured News & Press Releases

Oct 18, 2016: Domain Therapeutics and Medicxi launch Mavalon Therapeutics, aimed at halting the progression of Parkinson’s disease

Apr 14, 2014: Domain Therapeutics continues program to alter course of Parkinson’s disease with renewed support by The Michael J. Fox Foundation

Aug 29, 2012: Lilly Stops Phase III Development Of Pomaglumetad Methionil For Treatment Of Schizophrenia Based On Efficacy Results

Jul 11, 2012: Lilly Announces Pomaglumetad Methionil Did Not Meet Primary Endpoint Of Clinical Study

Mar 29, 2009: Lilly Announces Inconclusive Phase II Study Results For mGlu2/3 At The International Congress On Schizophrenia Research

Sep 02, 2007: Investigational Agent Targeting Metabotropic Glutamate 2/3 Receptors Demonstrates Antipsychotic Activity in Humans, Study in Nature Medicine Finds

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H1 2019

Number of Products under Development by Therapy Areas, H1 2019

Number ...

List of Tables

Number of Products under Development by Stage of Development, H1 2019

Number of Products under Development by Therapy Areas, H1 2019

Number of Products under Development by Indication, H1 2019

Number of Products under Development by Companies, H1 2019

Products under Development by Companies, H1 2019

Number of Products under Investigation by Universities/Institutes, H1 2019

Products under Investigation by Universities/Institutes, H1 2019

Number of Products by Stage and Mechanism of Actions, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Pipeline by Addex Therapeutics Ltd, H1 2019

Pipeline by Denovo Biopharma LLC, H1 2019

Pipeline by Domain Therapeutics SA, H1 2019

Pipeline by Eli Lilly and Co, H1 2019

Dormant Products, H1 2019

Dormant Products, H1 2019 (Contd..1), H1 2019

Discontinued Products, H1 2019

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H1 2019

Number of Products under Development by Therapy Areas, H1 2019

Number ...

List of Figures

Number of Products under Development by Stage of Development, H1 2019

Number of Products under Development by Therapy Areas, H1 2019

Number of Products under Development by Top 10 Indications, H1 2019

Number of Products by Mechanism of Actions, H1 2019

Number of Products by Stage and Mechanism of Actions, H1 2019

Number of Products by Route of Administration, H1 2019

Number of Products by Molecule Type, H1 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports